Every material Form 8-K Revolution Medicines, Inc. has filed with the SEC since September 01, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Revolution Medicines reported third-quarter 2026 results, its first quarter with commercial sales of RASONQUE after FDA approval on August 26, 2026. Net product revenue was $197.6 million, but the net loss rose to $407.5 million from $305.2 million a year earlier, as research, development and selling costs increased. The company reiterated its full-year 2026 GAAP operating expense guidance of $2.1 billion to $2.2 billion, and it said the quarter's sales included early-launch effects and should not be read as a sign of the longer-term trend.
Net product revenue of $197.6 million for the quarter ended September 30, 2026, covering about five weeks after FDA approval, with the company citing initial stocking of product in the channel
Net loss of $407.5 million, or $1.90 per share, versus a net loss of $305.2 million, or $1.61 per share, a year earlier; the loss included $40.7 million of non-cash warrant fair value charges
Research and development expenses were $417.1 million and SG&A expenses were $153.3 million, compared with $262.5 million and $52.8 million a year earlier
Cash, cash equivalents and marketable securities were $3.7 billion at September 30, 2026, excluding $250 million received in October from the first Royalty Pharma debt tranche
After the FDA approved RASONQUE (daraxonrasib) for metastatic pancreatic adenocarcinoma, Revolution Medicines borrowed a $250.0 million Tranche A loan from Royalty Pharma under a senior secured facility. The company also chose not to sell a Tranche 3 revenue participation right, which would have brought in up to $250.0 million, so it will not receive that payment.
Tranche A loan of $250.0 million advanced on October 8, 2026, with a $5.0 million draw fee paid to the lender.
Interest is three-month Term SOFR (3.50% floor) plus 5.75%, paid quarterly; the loan is interest-only and matures October 8, 2032.
Prepayment carries a make-whole amount plus a 3.0% premium before October 8, 2028, and smaller premiums afterward.
The company did not deliver a Tranche 3 Notice by October 10, 2026, forgoing a Tranche 3 Purchase Price of up to $250.0 million.
Revolution Medicines agreed on August 27, 2026 to lease four buildings totaling about 672,000 rentable square feet in Redwood City, California, for its new headquarters. The leases carry about $2.7 million in monthly base rent at full commencement, with about $115.9 million in landlord tenant improvement allowances, and are contingent on the landlords acquiring the properties.
Four leases cover about 672,000 rentable square feet at 1600, 1700, 1800 and 1900 Seaport Boulevard, with commencement dates from September 26, 2027 through September 1, 2028.
Initial lease terms end in September 2042, with three five-year extension options.
Aggregate base rent starts at about $2.7 million per month, rising about 3% annually, with about $23.1 million in base rent abatement through January 2030.
Leases are effective only if the landlords complete the Phase II Closing; they terminate automatically if it has not occurred by April 29, 2027.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Revolution Medicines, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →